Article Per Year (5 Year)
p-Index From 2021 - 2026
0.23
P-Index
This Author published in this journals
All Journal Journal of the Medical Sciences (Berkala Ilmu Kedokteran) Medicinus : Jurnal Kedokteran
Bachtiar Murtala
Department of Radiology, Faculty of Medicine, Universitas Hasanuddin, Makassar, Indonesia
Immunology & microbiology Medicine & Pharmacology Neuroscience Public Health

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

 1 
Factors affecting tumor response to transarterial chemoembolization (TACE) therapy in patient with hepatocellular carcinoma (HCC) Alia Amalia; Nikmatia Latief; Bachtiar Murtala; Andi Alfian Zainuddin; Nu’man AS Daud
Journal of the Medical Sciences (Berkala Ilmu Kedokteran) Vol 52, No 2 (2020)
Publisher : Journal of the Medical Sciences (Berkala Ilmu Kedokteran)

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (7775.512 KB) | DOI: 10.19106/JMedSci005202202006

Abstract

Hepatocellular carcinoma (HCC) is a major problem of global health.Transarterial chemoembolization (TACE) is the treatment of choice for unresectable HCC. The TACE is routinely conducted in major hospitals in Indonesia, however it rarely published.The use of modified response in evaluation criteria in solid tumors (mRECIST) was introduced as an accurate method of measuring tumor response in HCC. This study aimedto investigate the factorsaffecting tumor response to TACE therapy in HCC patients by using mRECIST. It was a retrospective cohort study conducted on 30 patients who successfully underwent the first TACE procedure in the Department of Radiology, Dr. Wahidin Sudirohusodo General Hospital, Makassar, Indonesia from January 2016 to August 2019. The multiphase abdominal computed tomography before and after as well as laboratory examination results before TACE were collected and analyzed. Chi-Square and Spearman-tests were used for the statistical analysis. A significant relationship between tumor location (p=0.016), number of tumor (p=0.001) and Child-Pugh score with tumor response to TACE therapy (p = 0.016) was observed. Solitary tumors tend to have a better therapeutic response, meanwhile, tumors located in the left lobe of patients with Child-Pugh B scores showed a decreased tumor response. Furthermore, no a significant relationship between age (p=0.920), sex (p=0.303), tumor size> 5 cm (p=0.082) and alpha-fetoprotein (AFP) levels (p=0.414) with tumor response was observed. In conclusion, TACE is preferably therapy for multinodular and unresectable HCC. Tumor response after TACE can be well assessed using mRECIST. The factorsaffecting tumor response to TACE therapy arenumber of tumor, location, and Child-Pugh score
Diagnostic Performance of PI-RADS v2.1 for Clinically Significant Prostate Cancer in Indonesian Patients Undergoing MRI Fusion Prostate Biopsy Nyoman Aditya Sindunata; Vera Nevyta Tarigan; Patricia Jorisal; Bachtiar Murtala; Marto Sugiono; Veli Sungono
Medicinus Vol. 15 No. 2 (2026): February
Publisher : Fakultas Kedokteran Universitas Pelita Harapan

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.19166/med.v15i2.10777

Abstract

Background: Prostate cancer is the second most common malignancy among men and one of the leading causes of cancer-related death. MRI evaluation using prostate imaging and data system (PI-RADS) v2.1 is widely applied to detect clinically significant prostate cancer (csPCa). However, data on its diagnostic performance in Indonesian population remain limited.   Methods: An analytical observational study with retrospective cross-sectional design was conducted on patients with PI-RADS category 3-5 who underwent MRI fusion prostate biopsy at Siloam Hospitals Kebon Jeruk between 2021 and 2025. Sensitivity, specificity, predictive values, and accuracy of PI-RADS v2.1 were evaluated against histopathological findings. Statistical analyses include Chi-Square and Mann-Whitney U test.   Result: A total of 75 patients were included, with a median age of 71 years (range: 49-84). The csPCa detection rates for each PI-RADS category were 14.29% for PI-RADS 3, 48.28% for PI-RADS 4 and 89.74% for PI-RADS 5. Histopathology confirmed csPCa in 50 patients (66.67%) and non-csPCa or benign lesions in 25 patients. The sensitivity of PI-RADS v2.1 at a cutoff ≥4 was 98% (95% CI 89.35–99.95), specificity 24% (95% CI 9.36–45.13), positive predictive value (PPV) 72.06%, negative predictive value (NPV) 85.71%, and overall accuracy 73.33% (95% CI 61.86–82.89). Bivariate analysis showed that older age, higher PSA, larger lesion size, PSA density ≥0.15 ng/ml2, and PIRADS 4/5 category were significantly associated with csPCa.   Conclusions: PI-RADS v2.1 demonstrates very high sensitivity and good NPV for excluding csPCa but has low specificity, resulting in moderate overall accuracy (73.33%).
Co-Authors Alia Amalia Andi Alfian Zainuddin Latief, Nikmatia Marto Sugiono Nu’man AS Daud Nyoman Aditya Sindunata Patricia Jorisal Veli Sungono Vera Nevyta Tarigan